

Commerce Finance and Policy Committee
Minnesota House of Representatives
St. Paul, Minnesota

March 13, 2023

Dear Distinguished Committee Members,

We are writing to express our **strong support for the Biomarker Testing (HF1978) bill**, which would require health plans to provide coverage for biomarker testing. Biomarkers are used to improve treatment precision. Improving treatment precision improves treatment outcomes and as a result, reduces cost over time. As healthcare professionals we can attest to the improvements in care that biomarkers have provided. There are several points that we encourage the committee to consider when evaluating this legislation.

1. The bill appropriately articulates strong requirements for scientific and medical evidence that would be relied on to mandate coverage of biomarker testing. These requirements are stringent, but adhere to standards that we already apply as healthcare professionals for a high level of evidence.
2. Appropriate use of biomarkers for prescribing the best drug and dose from the beginning can decrease costs over time due to improved treatment outcomes. The committee should be confident that the scientific and medical evidence required for payment in this bill will deter inappropriate use and will not excessively drive costs for payers. This is supported by the recent Dept of Commerce evaluation of economic impact.
3. Minnesota has inadequate insurance coverage for biomarkers by commercial payers and CMS. As an example, for pharmacogenomic biomarker testing, the CMS national coverage determination (NCD) is extraordinarily weak and there is no local coverage determination (LCD) in MN. We are one of only 10 remaining states without an LCD for pharmacogenomic biomarker testing. This has severely limited clinical utilization to patients with financial means to pay out of pocket. This adversely affects all Minnesotans, and perpetuates health disparities, especially the elderly and poor who cannot pay out of pocket, and denies safer and more effective therapy to those patients needing testing.
4. Minnesota has numerous healthcare professionals that are deeply educated and knowledgeable on biomarkers and have been part of evaluation of evidence and authoring of relevant biomarker guidelines and consensus statements. They would be willing to help equitably implement this bill into practice that does not economically harm our insurers while improving lives and reducing the suffering of Minnesotans.
5. The Minnesota Pharmacogenomics Consortium, led by the University of Minnesota and composed of healthcare professionals across the state, is a group that has collaborated for more than 4 years to drive improvements in medication management, appropriate incorporation of genomic guidance into patient care while reducing our medication expenditures. Our consortium will help facilitate appropriate use of genomic testing in Minnesota, if requested.
6. We recently surveyed over 800 Minnesotans about pharmacogenomic biomarkers. They expressed an overwhelming acceptability for these tests, but expected low out-of-pocket cost. In reality the full cost is the responsibility of most patients in Minnesota [PMID: 36294754].


7. We reviewed the economic analysis by the Dept of Commerce. It does not appear that the economic analysis accounted for the improved efficacy and safety of treatment using a biomarker-driven approach, which may offset the modest cost of obtaining biomarker testing.

As individuals with expertise in this field, we support this bill. Thank you for the opportunity to comment.

Sincerely,



Pamala Jacobson, PharmD, FCCP



Jeffrey R. Bishop, PharmD, FCCP

Members of Statewide Pharmacogenomics Consortium		
<i>Individual</i>	<i>Contact Information</i>	<i>Place of Work</i>
Pamala Jacobson, PharmD, FCCP (co-chair)	jacob117@umn.edu	University of Minnesota
Jeffrey Bishop, PharmD, BCPP, FCCP (co-chair)	jrbishop@umn.edu	University of Minnesota
Jacob Brown, PharmD, MS	jtbrown@d.umn.edu	University of Minnesota - Duluth
Tiana Butler, PharmD, BCPS	tiana.luczak@fairview.org	M Health Fairview
Elise Durgin, PharmD, BCPS	elise.durgin@cuyunamed.org	Cuyuna Medical Center
David Gregornik, PharmD, BCOP	david.gregornik@childrensmn.org	Children's Minnesota
Elisa Houwick, MD., PhD	Houwink.Elisa@mayo.edu	Mayo Clinic
Steve Johnson, PhD	joh06288@umn.edu	University of Minnesota
Christine Kroger, PharmD, BCACP	Christine.Kroger@allina.com	Allina Health
Susie Long, PharmD	Susie.Long@fairview.org	M Health Fairview
Pawel Mroz, MD, PhD	pmroz@umn.edu	University of Minnesota
Wayne (Nick) Nicholson, MD, PharmD	Nicholson.Wayne@mayo.edu	Mayo Clinic
Pamala Pawloski, PharmD	Pamala.A.Pawloski@healthpartners.com	Health Partners
David Stenehjem, PharmD, BCOP	stene032@d.umn.edu	University of Minnesota - Duluth
Tyler Stevens, PharmD	tyler.stevens@essentiahealth.org	Essentia Health
Robert Straka, PharmD, FCCP	strak001@umn.edu	University of Minnesota